CTRI/2019/11/021838尚未招募4 期
Efficacy and Safety of Edaravone in Amyotrophic Lateral Sclerosis - ESEALS
ARMED FORCES MEDICAL RESEARCH COMMITY0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •Patients, who are more than 18 years of age and are diagnosed to have possible, probable or definite ALS as per the El Escorial Criteria 2014, will be included.
排除标准
- •Patients will be excluded if they have liver or kidney disorder (eGFR < 50ml/min), malignancy, uncontrolled hypertension, or any structural brain or spinal cord lesion
研究者
相似试验
已完成
1 期
The Safety of Edaravone for patients with Amyotrophic Lateral Sclerosis: Single centered open label trialamyotrophic lateral sclerosisJPRN-UMIN000016352Ehime University Hospital10
已完成
1 期
Clinical Pharmacology Study of Oral Edaravone in Amyotrophic Lateral Sclerosis Patients With GastrostomyJapanese Patients With ALSNCT04254913Shionogi6
尚未招募
3 期
Effectivnes of edaravone on ischemic strokeIschemic stroke.Cerebral infarctionIRCT20240224061102N1Yasouj University of Medical Sciences60
已完成
不适用
Clinical study of the effectiveness of edaravone for the oxidative stress in amyotrophic lateral sclerosisAmyotrophic Lateral Sclerosis (ALS)JPRN-UMIN000024854Okayama university20
已完成
3 期
Edaravone in COVID-19IRCT20200317046797N6Tabriz University of Medical Sciences30